Clinical Trial

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma

Study acronym: NIPU
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 29, 2024 (before its estimated March 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
The objective of the study is to induce a meaningful progression-free survival benefit in patients with Malign Pleural Mesothelioma (MPM) after progression on first line standard platinum doublet chemotherapy, by treating with nivolumab and ipilimumab with or without UV1 vaccine.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-03-05; most recent amendment 2024-02-28.
Status change: Recruiting → Active, Not Recruiting 2023-01-23
Status change: Not Yet Recruiting → Recruiting 2020-06-29
Trial Details
NCT Number NCT04300244
Lead Sponsor Åslaug Helland
Collaborators: Oslo University Hospital, Ultimovacs ASA, Bristol-Myers Squibb
Conditions Cancer, Cancer, Lung, Cancer of Lung, Mesothelioma, Mesothelioma; Lung, Mesothelioma; Pleura, Mesotheliomas Pleural
Enrollment 118 participants
Start Date 2020-05-04
Primary Completion 2025-03-15 (estimated)
Study Completion 2027-03-15 (estimated)
Updated on ClinicalTrials.gov 2024-02-29